纳武利尤单抗联合伊匹木单抗治疗晚期黑色素瘤的安全性汇总分析
该汇总分析基于三项临床试验的448例晚期黑色素瘤患者,评估纳武利尤单抗1 mg/kg联合伊匹木单抗3 mg/kg方案的安全性。治疗相关3/4级不良事件发生率为55.5%,35.7%的患者因不良事件停药,4例(<1%)研究期间死亡归因于治疗。
要点
- 治疗相关3/4级不良事件发生率为55.5%,35.7%的患者因此停药。
- 最常见任何级别选择性不良事件为皮肤(64.3%)和胃肠道(46.7%)。
- 3/4级选择性不良事件中肝脏(17.0%)和胃肠道(16.3%)最常见。
核心结论
- 纳武利尤单抗联合伊匹木单抗的3/4级治疗相关不良事件发生率高于任一单药的历史经验且发生更早,但缓解率相似。
研究设计与样本
- 回顾性安全性分析,汇总三项临床试验(I期、II期和III期)中接受至少一剂纳武利尤单抗1 mg/kg联合伊匹木单抗3 mg/kg每3周×4次、随后纳武利尤单抗3 mg/kg每2周直至疾病进展或不可接受毒性的晚期黑色素瘤患者,共448例。
主要发现
- 中位随访时间为13.2个月。
- 治疗相关3/4级不良事件发生于55.5%的患者;35.7%的患者因治疗相关不良事件停药。
- 任何级别最常见的治疗相关选择性不良事件为皮肤(64.3%)和胃肠道(46.7%);3/4级中肝脏(17.0%)和胃肠道(16.3%)最常见。
- 30.1%的患者在超过一个器官类别中发生2至4级选择性不良事件。
- 3/4级治疗相关选择性不良事件的中位发生时间从3.1周(皮肤)至16.3周(肾脏);除内分泌不良事件外,从发生到缓解的中位时间从1.9周(肾脏)至4.5周(肺部),缓解率在79%至100%之间,同时使用免疫调节剂。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose The addition of nivolumab (anti-programmed death-1 antibody) to ipilimumab (anti-cytotoxic T-cell lymphocyte-associated 4 antibody) in patients with advanced melanoma improves antitumor response and progression-free survival but with a higher frequency of adverse events (AEs). This cross-melanoma study describes the safety profile of the approved nivolumab plus ipilimumab regimen. Methods This retrospective safety review on data from three trials (phase I, II, and III) included patients with advanced melanoma who received at least one dose of nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks × 4 and then nivolumab 3 mg/kg every 2 weeks until disease progression or unacceptable toxicity while following established guidelines for AE management. Analyses were of all treatment-related AEs, select (immune-related) AEs, time to onset and resolution, and use of immune-modulating agents and their effects on outcome. Results Among 448 patients, median duration of follow-up was 13.2 months. Treatment-related grade 3/4 AEs occurred in 55.5% of patients; 35.7% had treatment-related AEs that led to discontinuation. The most frequent treatment-related select AEs of any grade were skin (64.3%) and GI (46.7%) and of grade 3/4, hepatic (17.0%) and GI (16.3%); 30.1% developed a grade 2 to 4 select AE in more than one organ category. Median time to onset of grade 3/4 treatment-related select AEs ranged from 3.1 (skin) to 16.3 (renal) weeks, and with the exclusion of endocrine AEs, median time to resolution from onset ranged from 1.9 (renal) to 4.5 (pulmonary) weeks, with resolution rates between 79% and 100% while using immune-modulating agents. Four (< 1%) on-study deaths were attributed to therapy. Conclusion Frequency of grade 3/4 treatment-related AEs was higher with nivolumab plus ipilimumab and occurred earlier than historical experience with either agent alone, but resolution rates were similar.
引用
- Sznol M, Ferrucci PF, Hogg D, et al. Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. J Clin Oncol. 2017. PMID: 28915085. doi:10.1200/JCO.2016.72.1167
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。